--- title: Radiopharmaceutical Insights | Manufacturing News & Expert Perspectives description: Access radiopharmaceutical manufacturing news, trends, and expert insights across development, commercialization, and patient impact. --- Beyond the breakthrough # Radiopharmaceuticals. Science is only half the story. Radiopharmaceutical innovation accelerates with success depending on more than eureka moments. Explore expert perspectives on the operational, regulatory and commercial realities framing the future.  The Institute@Precision Radiopharmaceuticals Series Research & Development ### Advancing Radiopharmaceuticals From Regulatory Approval to Global Access [Read More](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Advancing%20Radiopharmaceuticals%20Global%20Access.pdf) Commercialization & Access ### Wall Street Perspective on Radiopharmaceuticals [Read More](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Wall%20Street%20Perspective%20Radiopharma.pdf) Research & Development ### Navigating Global Regulations for Radiopharmaceutical Development [Read More](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Navigating%20Global%20Regulations%20for%20Radiopharmaceutical%20Development.pdf) Commercialization & Access ### Challenges and Opportunities for Radiopharmaceutical Commercialization [Read More](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Challenges%20and%20Opportunities%20for%20Radiopharmaceutical%20Commercialization.pdf) Research & Development ### Managing Operational Complexity in Early-Phase Oncology Radiopharmaceutical Trials [Read More](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Managing%20Operational%20Complexity.pdf) ![Advancing Radiopharmaceuticals From Regulatory Approval to Global Access Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/Advancing%20Radiopharmaceuticals%20From%20Regulatory%20Approval%20to%20Global%20Access.jpg?length=720&name=Advancing%20Radiopharmaceuticals%20From%20Regulatory%20Approval%20to%20Global%20Access.jpg) Research & Development | White Paper Advancing Radiopharmaceuticals From Regulatory Approval to Global Access [ Read More ](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Advancing%20Radiopharmaceuticals%20Global%20Access.pdf) ![Wall Street Perspective on Radiopharmaceuticals Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/Wall%20Street%20Perspective%20on%20Radiopharmaceuticals.jpg?length=720&name=Wall%20Street%20Perspective%20on%20Radiopharmaceuticals.jpg) Commercialization & Access | White Paper Wall Street Perspective on Radiopharmaceuticals [ Read More ](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Wall%20Street%20Perspective%20Radiopharma.pdf) ![Navigating Global Regulations for Radiopharmaceutical Development Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/Navigating%20Global%20Regulations%20for%20Radiopharmaceutical%20Development.jpg?length=720&name=Navigating%20Global%20Regulations%20for%20Radiopharmaceutical%20Development.jpg) Research & Development | White Paper Navigating Global Regulations for Radiopharmaceutical Development [ Read More ](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Navigating%20Global%20Regulations%20for%20Radiopharmaceutical%20Development.pdf) ![Challenges and Opportunities for Radiopharmaceutical Commercialization Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/Challenges%20and%20Opportunities%20for%20Radiopharmaceutical%20Commercialization.jpg?length=720&name=Challenges%20and%20Opportunities%20for%20Radiopharmaceutical%20Commercialization.jpg) Commercialization & Access | White Paper Challenges and Opportunities for Radiopharmaceutical Commercialization [ Read More ](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Challenges%20and%20Opportunities%20for%20Radiopharmaceutical%20Commercialization.pdf) ![Managing Operational Complexity in Early-Phase Oncology Radiopharmaceutical Trials Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/Managing%20Operational%20Complexity%20in%20Early-Phase%20Oncology%20Radiopharmaceutical%20Trials.jpg?length=720&name=Managing%20Operational%20Complexity%20in%20Early-Phase%20Oncology%20Radiopharmaceutical%20Trials.jpg) Research & Development | White Paper Managing Operational Complexity in Early-Phase Oncology Radiopharmaceutical Trials [ Read More ](https://www.instituteatprecision.com/hubfs/Institute%20at%20Precision%20Website/Asset%20Files/I@P-Managing%20Operational%20Complexity.pdf) Navigating the landscape ## The path from promise to practice Decisions made in one area can create opportunities, or constraints, across the entire product lifecycle.   ![radiopharm-topic-page-card-1-opt2](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Images/radiopharm-topic-page-card-1-opt2.webp?length=720&name=radiopharm-topic-page-card-1-opt2.webp) Development Designing for reality early Radiopharmaceutical development demands early consideration of access, infrastructure and evidence. Decisions made during trial planning can influence success long after approval.  ![radiopharm-topic-page-card-2](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Images/radiopharm-topic-page-card-2.webp?length=720&name=radiopharm-topic-page-card-2.webp) Operations Keeping progress moving forward Short half-lives, site readiness and supply co-ordination leave little room for error. Understanding operational pressure points can help prevent a delay becoming a roadblock.   ![radiopharm-topic-page-card3](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Images/radiopharm-topic-page-card3.webp?length=720&name=radiopharm-topic-page-card3.webp) Commercialization Accelerating into adoption Approval is just the gateway. Reimbursement, provider readiness and community activation all influence whether radiopharmaceutical innovation reaches its full potential.  Radiopharm excellence ## Expertise has no half-life Precision teams make sense of the science and logistics of radiopharmaceutical therapies, from development to access and adoption.   ![Greg Gregory, PhD Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Greg%20Gregory.png?length=720&name=Greg%20Gregory.png) Precision AQ Greg Gregory, PhD [ Find out more ](https://www.instituteatprecision.com/experts/greg-gregory) ![Stephanie Kennedy, PhD Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Stephanie%20Kennedy.png?length=720&name=Stephanie%20Kennedy.png) Precision AQ Stephanie Kennedy, PhD [ Find out more ](https://www.instituteatprecision.com/experts/stephanie-kennedy) ![Julianna Kula, PharmD, BCOP Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Julianna%20Kula.png?length=720&name=Julianna%20Kula.png) Precision AQ Julianna Kula, PharmD, BCOP [ Find out more ](https://www.instituteatprecision.com/experts/julianna-kula) ![Angelica Norrell, PharmD, BCOP, CSP Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Angelica%20Norrell.png?length=720&name=Angelica%20Norrell.png) Precision AQ Angelica Norrell, PharmD, BCOP, CSP [ Find out more ](https://www.instituteatprecision.com/experts/angelica-norrell) ![Cherry Moldovan, PhD Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Cherry%20Moldovan.png?length=720&name=Cherry%20Moldovan.png) Precision AQ Cherry Moldovan, PhD [ Find out more ](https://www.instituteatprecision.com/experts/cherry-moldovan) ![Hannah Deresiewicz Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Hannah%20Deresewicz.png?length=720&name=Hannah%20Deresewicz.png) Precision AQ Hannah Deresiewicz [ Find out more ](https://www.instituteatprecision.com/experts/hannah-deresiewicz) ![Anne Marie Fields Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Anne%20Marie%20Fields.png?length=720&name=Anne%20Marie%20Fields.png) Precision AQ Anne Marie Fields [ Find out more ](https://www.instituteatprecision.com/experts/anne-marie-fields) ![Andrew Dymon Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Andrew%20Dymon.png?length=720&name=Andrew%20Dymon.png) Precision AQ Andrew Dymon [ Find out more ](https://www.instituteatprecision.com/experts/andrew-dymon) ![Nicholas Richardson, DO, MPH Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Nicholas%20Richardson.png?length=720&name=Nicholas%20Richardson.png) Precision for Medicine Nicholas Richardson, DO, MPH [ Find out more ](https://www.instituteatprecision.com/experts/nicholas-richardson) ![John McIntyre, PhD Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/John%20McIntyre.png?length=720&name=John%20McIntyre.png) Precision for Medicine John McIntyre, PhD [ Find out more ](https://www.instituteatprecision.com/experts/john-mcintyre) ![Harpreet Singh, MD Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Harpreet%20Singh.png?length=720&name=Harpreet%20Singh.png) Precision for Medicine Harpreet Singh, MD [ Find out more ](https://www.instituteatprecision.com/experts/harpreet-singh) ![Jing Ping Yeo, PhD, MBA Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Jing%20Ping%20Yeo.png?length=720&name=Jing%20Ping%20Yeo.png) Precision for Medicine Jing Ping Yeo, PhD, MBA [ Find out more ](https://www.instituteatprecision.com/experts/jing-ping-yeo) ![Geoffrey Kannan, PhD, MD Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Geoffrey%20Kannan.png?length=720&name=Geoffrey%20Kannan.png) Precision for Medicine Geoffrey Kannan, PhD, MD [ Find out more ](https://www.instituteatprecision.com/experts/geoffrey-kannan) ![Ivan Barrera, MD Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Ivan%20Barrera.png?length=720&name=Ivan%20Barrera.png) Precision for Medicine Ivan Barrera, MD [ Find out more ](https://www.instituteatprecision.com/experts/ivan-barrera) ![Robert Bauer Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Bob%20Bauer.png?length=720&name=Bob%20Bauer.png) Precision for Medicine Robert Bauer [ Find out more ](https://www.instituteatprecision.com/experts/robert-bauer) ![Kurt Preugschat Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Expert%20Headshots/Kurt%20Preugschat.png?length=720&name=Kurt%20Preugschat.png) Precision for Medicine Kurt Preugschat [ Find out more ](https://www.instituteatprecision.com/experts/kurt-preugschat) What’s next ## Stay tuned Keep up with the insights helping teams stay one step ahead, from emerging regulations and operational realities to commercialization strategies and market trends.   Subscribe   Questions answered ## Radiopharma FAQs Explore answers to some of the most common questions surrounding radiopharma, from innovation to clinical trials, regulation and patient access.   What are radiopharmaceuticals? These are medicines containing radioactive isotopes that can be used to diagnose and treat disease. In oncology, they offer a targeted approach by delivering radiation directly to tumor cells while limiting exposure to healthy tissues.   Why are radiopharmaceuticals gaining momentum? In oncology, they offer a targeted approach by delivering radiation directly to tumor cells while limiting exposure to healthy tissue. How is radiopharmaceutical development different from other therapies? Radiopharmaceuticals introduce unique scientific and operational considerations. Short isotope half-lives, specialized manufacturing requirements and complex logistics can create challenges rarely encountered in traditional drug development.  What can delay radiopharmaceutical trials? Site readiness, isotope availability, logistics, patient scheduling and regulatory requirements can all create bottlenecks. Identifying operational risks early can help reduce disruption.  Why are global regulations so complex? Regulatory frameworks vary across regions and often reflect differences in healthcare systems, nuclear medicine infrastructure and local requirements. Understanding these differences early can help avoid delays.  Does approval guarantee patient access? No. Regulatory approval is a significant milestone, but it is only one step in the journey. Reimbursement pathways, treatment infrastructure and healthcare system readiness all influence patient access.  What are the biggest commercialization challenges? Commercialization requires aligning providers, treatment centers, payers and healthcare systems. Capacity constraints, reimbursement considerations and operational complexity can all affect uptake.  What will shape radiopharma's future? Innovation in targeting technologies, isotope development and combination therapies will help shape the future of the field, alongside advances in manufacturing, supply infrastructure and patient access.